Literature DB >> 7801901

Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue.

T Plesner1, E Ralfkiaer, M Wittrup, H Johnsen, C Pyke, T L Pedersen, N E Hansen, K Danø.   

Abstract

Expression of the receptor for the urokinase type plasminogen activator (uPAR) has been studied by flow cytometry and immunohistology in normal blood and bone marrow cells, in vitro activated lymphoid cells, and tissue samples from reactive lymph nodes (n = 6), thymus (n = 2) and malignant lymphomas (n = 82), or leukemias (n = 32). HL-60 myeloid precursor cells and CD34-positive normal stem cells also were analyzed. In the normal cells, staining was confined to monocytes, macrophages, neutrophils, and myeloid precursors. No labelling was seen of normal or activated lymphoid cells. Purified CD34-positive hematopoietic progenitors were uPAR negative, but expressed uPAR during differentiation in short-term liquid culture stimulated in vitro by recombinant interleukin (IL)-1, IL-3, IL-6, granulocyte-macrophage colony stimulating factor (CSF), granulocyte-CSF, and stem cell factor. Enhanced uPAR expression was also seen in HL-60 cells after induction of differentiation with dimethyl sulfoxide or 1 alpha,25-dihydroxyvitamin D3. In lymphomas and leukemias, the staining pattern was similar to that seen in the normal cells with labelling of monocytic and myeloid that seen in the normal cells with labelling of monocytic and myeloid malignancies, but not of the neoplastic cells in B-cell or T-cell lymphomas or Hodgkin's disease. In conclusion, uPAR is a differentiation marker for myeloid and monocytic cells, and may act to facilitate migration of these cells in normal and pathologic conditions by cell-associated plasminogen activation. Whether expression of uPAR in myeloid and monocytic malignancies relates to their growth and behavior will be an important topic for investigations in the future.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7801901     DOI: 10.1093/ajcp/102.6.835

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  23 in total

1.  Role of urokinase plasminogen activator receptor (CD87) as a prognostic marker in acute myeloid leukemia.

Authors:  Maha Atfy; Mohamad Eissa; Hossam E Salah; Deena A El Shabrawy
Journal:  Med Oncol       Date:  2011-06-03       Impact factor: 3.064

2.  Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.

Authors:  Andrew S Gilder; Karra A Jones; Jingjing Hu; Lei Wang; Clark C Chen; Bob S Carter; Steven L Gonias
Journal:  J Biol Chem       Date:  2015-04-02       Impact factor: 5.157

Review 3.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

4.  Macrophage-dependent cleavage of the laminin receptor α6β1 in prostate cancer.

Authors:  Isis C Sroka; Cynthia P Sandoval; Harsharon Chopra; Jaime M C Gard; Sangita C Pawar; Anne E Cress
Journal:  Mol Cancer Res       Date:  2011-08-08       Impact factor: 5.852

5.  Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis.

Authors:  Timmy Mani; Fang Wang; William Eric Knabe; Anthony L Sinn; May Khanna; Inha Jo; George E Sandusky; George W Sledge; David R Jones; Rajesh Khanna; Karen E Pollok; Samy O Meroueh
Journal:  Bioorg Med Chem       Date:  2013-01-09       Impact factor: 3.641

6.  Preparation and antitumor effect of a toxin-linked conjugate targeting vascular endothelial growth factor receptor and urokinase plasminogen activator.

Authors:  Ying Xiang; Qiying Li; Dehong Huang; Xianjun Tang; Li Wang; Yang Shi; Wenjun Zhang; Tao Yang; Chunyan Xiao; Jianghong Wang
Journal:  Exp Biol Med (Maywood)       Date:  2014-08-14

7.  Fibrinolytic cross-talk: a new mechanism for plasmin formation.

Authors:  Tiphaine Dejouvencel; Loïc Doeuvre; Romaric Lacroix; Laurent Plawinski; Françoise Dignat-George; H Roger Lijnen; Eduardo Anglés-Cano
Journal:  Blood       Date:  2009-12-07       Impact factor: 22.113

Review 8.  Regulation of cell signalling by uPAR.

Authors:  Harvey W Smith; Chris J Marshall
Journal:  Nat Rev Mol Cell Biol       Date:  2010-01       Impact factor: 94.444

9.  Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI.

Authors:  Tariq U Azam; Husam R Shadid; Pennelope Blakely; Patrick O'Hayer; Hanna Berlin; Michael Pan; Peiyao Zhao; Lili Zhao; Subramaniam Pennathur; Rodica Pop-Busui; Izzet Altintas; Jens Tingleff; Marius A Stauning; Ove Andersen; Maria-Evangelia Adami; Nicky Solomonidi; Maria Tsilika; Pinkus Tober-Lau; Eleni Arnaoutoglou; Verena Keitel; Frank Tacke; Athanasios Chalkias; Sven H Loosen; Evangelos J Giamarellos-Bourboulis; Jesper Eugen-Olsen; Jochen Reiser; Salim S Hayek
Journal:  J Am Soc Nephrol       Date:  2020-09-22       Impact factor: 10.121

10.  A CCR2 macrophage endocytic pathway mediates extravascular fibrin clearance in vivo.

Authors:  Michael P Motley; Daniel H Madsen; Henrik J Jürgensen; David E Spencer; Roman Szabo; Kenn Holmbeck; Matthew J Flick; Daniel A Lawrence; Francis J Castellino; Roberto Weigert; Thomas H Bugge
Journal:  Blood       Date:  2015-12-08       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.